News
4D Molecular Therapeutics Q1 2024 GAAP EPS $(0.66) Beats $(0.78) Estimate
9 May 24
Earnings, Earnings Beats, News
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
18 Apr 24
Long Ideas, Short Ideas, Trading Ideas, ETFs
RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $40
15 Apr 24
News, Price Target, Analyst Ratings
Barclays Initiates Coverage On 4D Molecular Therapeutics with Overweight Rating, Announces Price Target of $45
15 Apr 24
News, Price Target, Initiation, Analyst Ratings
BMO Capital Maintains Outperform on 4D Molecular Therapeutics, Lowers Price Target to $63
1 Apr 24
News, Price Target, Analyst Ratings
Jefferies Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $58
1 Apr 24
News, Price Target, Analyst Ratings
4D Molecular Therapeutics Outlines Pivotal Development Plans For Cystic Fibrosis, Rare Inherited Disease
28 Mar 24
Biotech, News, Health Care, FDA, Movers, General
4DMT Announces Update On Regulatory Interactions And Development Path For 4D-710 For Treatment Of Cystic Fibrosis
28 Mar 24
Biotech, News, General
4D Molecular Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
1 Mar 24
Analyst Ratings
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
1 Mar 24
News, Price Target, Reiteration, Analyst Ratings
4DMT FY23 EPS $(2.58) Vs $(3.32) YoY
29 Feb 24
Earnings, News
4DMT Presents Interim Data From 4D-310 INGLAXA Phase 1/2 Clinical Trials For Fabry Disease Cardiomyopathy At WORLDSymposium 2024
12 Feb 24
Biotech, News, General